Stay updated on Expanded Access to Upadacitinib Clinical Trial
Sign up to get notified when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.
Latest updates to the Expanded Access to Upadacitinib Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision history shows a new entry v3.3.2 and removal of v3.2.0. No substantive study content or eligibility details were changed.SummaryDifference0.1%
- Check20 days agoChange DetectedThe government funding/operating status notice was removed from the page. No core study information such as eligibility criteria, interventions, or contact details appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check34 days agoChange DetectedThe new screenshot shows minor visual/layout adjustments to the study page, while core study details (conditions, eligibility criteria, and contact information) remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check63 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference8%
- Check70 days agoChange DetectedUpdate: version bumped to v3.1.0 with a new contact phone number 844-663-3742; previous version v3.0.2 removed.SummaryDifference0.2%
- Check77 days agoChange DetectedExpanded disease coverage and metadata (new diseases, categories, and identifiers) with updated timestamps; some old age-range and prior update-label details were removed.SummaryDifference9%
Stay in the know with updates to Expanded Access to Upadacitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.